The CTVG combines expertise in immunology, immunotherapies and advanced in vitro and in vivo models. The CTVG group is led by John Maris, Karin Straathoff and Stefan Pfister, with members Laura Donovan, Jarno Drost, Alexander Eggermont, Anne C. Rios, Nikolaos G. Sgourakis, Rob Wechsler-Reya, Brandon Wainwright and industry partners BioNTech, Myrio Therapeutics and AstraZeneca.